Skip to content

Search Results

No Matching Results

    Recently Viewed

      Listening...

      HomeLatest newsWhat you need to know about Johnson & Johnson’s 2024 first-quarter earnings
      Q1 2024-1x1.png

      What you need to know about Johnson & Johnson’s 2024 first-quarter earnings

      Here’s an infographic breakdown of the company’s first-quarter earnings results, including key highlights from its Innovative Medicine and MedTech businesses.

      Share Article
      share to

      This morning, Johnson & Johnson shared its 2024 first-quarter earnings report.

      Since its founding in 1886 the company has been committed to innovation—today, more than 130,000 employees across the globe work to deliver solutions for patients around the world and to help profoundly impact health for humanity.

      “This quarter’s solid financial results and the significant advancement of our pipeline further progressed our business toward future growth,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “Our strong financial foundation and commitment to operational excellence enables us to continue to invest in innovation that delivers novel treatments for our patients, enhance our portfolio through strategic acquisitions, and return capital for our shareholders, as evidenced by our 62nd consecutive year of dividend increases announced today

      For more details about the company’s 2024 first-quarter results and to read a message from Chairman and Chief Executive Officer Joaquin Duato, here’s an infographic highlighting key stats.


      Q1 2024 Earnings Infographic

      Johnson & Johnson’s 2024 1st-quarter earnings

      Read the earnings press release, which includes full financial data for the first quarter of 2024.

      Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

      More from Johnson & Johnson

      Meet a nurse who leads clinical trials to find innovative cancer therapies

      Melissa Martinez is a clinical scientist within Johnson & Johnson’s Interventional Oncology R&D group. Not only is she helping to develop lifesaving treatments, she’s redefining what it means to pursue a career in nursing.

      What’s the difference between IBS and IBD?

      These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

      What is IL-23?

      This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.